Tuesday, April 5, 2022

Huntsworth adds Big Pharma-focused medical communications group Nucleus Global to its network


From molecule to medicine—that’s how Huntsworth describes its offerings now that it has acquired Nucleus Global.

Huntsworth, the parent company of Evoke Group, is adding the global medical specialist communications group during COVID-19 in a swift acquisition that initiated and closed within three months. 

While that means Hunstworth CEO Paul Taaffe has yet to meet his new colleagues face to face, the screen-to-screen interactions have been just as effective in putting together what he calls one of the largest high science communications teams in the world.

Free Webinar

Hindsight is so 2020 – Getting Ahead of CNS Trial Enrollment in a Rapidly Changing Clinical Landscape

The past six months have highlighted both existing and unexpected enrollment challenges, as sponsors, CROs, and sites have been pressed to evolve their recruitment strategies. Join us as Rho experts discuss their approach to adapting CNS trial enrollment to a rapidly changing clinical landscape. Register now.

With very little overlap between the two companies, Taaffe sees only enhancement with the addition of Nucleus to the fold. Huntsworth lends itself more towards biotech through its MediStrava business, while Nucleus gears more toward Big Pharma.

RELATED: Evoke Group’s expansion drive continues with West Coast agency buy

Looking across the newly approved drug landscape from five years ago and up through today’s pipeline, the emphasis has been on high science and moving toward personalized medicine, Taaffe said. That means pharma companies need more and more scientific expertise in medical communications.

While Huntsworth is now pretty much a one-stop-shop for biotech and pharma, there are two types of operations that Taaffe has no plans to add—drug trials or running a salesforce. There’s plenty to do without adding them to the list.

“We have a view that the long-term growth—notwithstanding COVID and some disruption on trials—and the creation of new drugs is high. You’re seeing more and more drugs go into a trial, and more and more drugs getting approved,” he said.

RELATED: On heels of big New York hire, Evoke vaults to top ranks in health communications with Kyne buyout

Nucleus will add 800 experts across 14 offices to Huntsworth’s growing network of four healthcare operating units: Huntsworth, MediStrava, the Evoke Group and The Creative Engagement Group.

Stephen Cameron, Nucleus’ founder and chairman, will stay on as head of Nucleus and will join the Huntsworth board. This is the company’s second acquisition since it was bought by private equity firm Clayton, Dubilier & Rice.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...